SCC
Zecen
DR1019
| Quantity: | |
|---|---|
SCC is a group of glycoprotein of serine/cysteine protease inhibitor family, with molecular weight of 45,000 Daltons. SCC was originally isolated from squamous cell carcinoma by Kato and etc. It is composed of at least 10 different subunits of isoelectric points.
In the diagnosis of cervical cancer: SCC sensitivity of primary cervical squamous cell carcinoma was 44% -69%; of recurrent cancer was 67% to 100% , and specificity is 90% -96%; its serum level is related with tumor development, extent of violations and metastasis. After radical operation of cervical cancer, SCC decreased significantly; SCC can prompt early recurrence, for 50% of patients, elevated level of SCC is 2-5 months earlier than the clinical diagnosis, which can be applied as an independent risk factor. SCC assists the diagnosis of lung squamous cell carcinoma.
It is related with SCC tumor progression. Combined with CA125, CYFRA21-1 and CEA, it will improve the diagnostic sensitivity of lung cancer. For ESCC prediction, SCC increased with progression of the disease. For patients with advanced disease, the sensitivity can be up to 73%.
Combined with CYFRA21-1, it can improve the detection sensitivity. In addition, SCC also plays an important role in other cancers (such as: head and neck cancer, vulvar cancer, bladder cancer,
anal cancer, skin cancer, etc.)
Actors affecting the detectability of SCCA in serum
Tumor size and volume (more tumor cells result in a larger amount of SCCA);
Invasiveness of the primary tumor or recurrence;
Lymph node metastasis (LNM) (secreted SCCA from tumor cells in lymph nodes is easily detected in the bloodstream);
Distant metastasis (circulating tumor cells enable easy detection of secreted SCCA in blood tests);
Impairment of immunosurveillance.
SCC is a group of glycoprotein of serine/cysteine protease inhibitor family, with molecular weight of 45,000 Daltons. SCC was originally isolated from squamous cell carcinoma by Kato and etc. It is composed of at least 10 different subunits of isoelectric points.
In the diagnosis of cervical cancer: SCC sensitivity of primary cervical squamous cell carcinoma was 44% -69%; of recurrent cancer was 67% to 100% , and specificity is 90% -96%; its serum level is related with tumor development, extent of violations and metastasis. After radical operation of cervical cancer, SCC decreased significantly; SCC can prompt early recurrence, for 50% of patients, elevated level of SCC is 2-5 months earlier than the clinical diagnosis, which can be applied as an independent risk factor. SCC assists the diagnosis of lung squamous cell carcinoma.
It is related with SCC tumor progression. Combined with CA125, CYFRA21-1 and CEA, it will improve the diagnostic sensitivity of lung cancer. For ESCC prediction, SCC increased with progression of the disease. For patients with advanced disease, the sensitivity can be up to 73%.
Combined with CYFRA21-1, it can improve the detection sensitivity. In addition, SCC also plays an important role in other cancers (such as: head and neck cancer, vulvar cancer, bladder cancer,
anal cancer, skin cancer, etc.)
Actors affecting the detectability of SCCA in serum
Tumor size and volume (more tumor cells result in a larger amount of SCCA);
Invasiveness of the primary tumor or recurrence;
Lymph node metastasis (LNM) (secreted SCCA from tumor cells in lymph nodes is easily detected in the bloodstream);
Distant metastasis (circulating tumor cells enable easy detection of secreted SCCA in blood tests);
Impairment of immunosurveillance.
